ReviewIranian journal of pharmaceutical research : IJPR
Recent Progress in PET and SPECT Myocardial Perfusion Imaging: From Radiopharmaceuticals to Imaging Innovations.
Review in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality worldwide, underscoring the need for accurate, noninvasive diagnostic methods to support clinical decision-making and treatment planning. Myocardial perfusion imaging (MPI) with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) plays a key role in the evaluation of myocardial ischemia and coronary artery disease. This review provides a comparative overview of PET and SPECT MPI, with particular emphasis on radiopharmaceuticals, technical advances, clinical applications, and the limitations of each modality. Evidence Acquisition: A systematic literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar for studies published between 1990 and July 2026. Search terms included myocardial perfusion imaging, PET radiotracers, SPECT radiotracers, rubidium-82, nitrogen-13 ammonia, technetium-99m sestamibi, flurpiridaz, and relevant combinations of these terms using Boolean operators. Original research articles, clinical trials, and review articles addressing radiopharmaceutical development, image reconstruction techniques, quantitative imaging, and hybrid PET/CT and SPECT/CT technologies were included. Non-English publications, case reports, and studies lacking relevant original or comparative data were excluded. The reference lists of eligible articles were also manually reviewed. Radiotracers were compared with respect to pharmacokinetics, myocardial extraction fraction, target-to-background ratio, image quality, radiation dosimetry, and clinical utility. Results: SPECT MPI, particularly with Conclusions: PET and SPECT play important and complementary roles in noninvasive myocardial perfusion imaging. SPECT remains the most widely available and cost-effective technique, whereas PET provides superior image quality, attenuation correction, and quantitative assessment of myocardial blood flow. Ongoing advances in radiopharmaceutical development, hybrid imaging systems, reconstruction methods, and quantitative software are expected to further enhance the diagnostic and prognostic value of MPI and support increasingly personalized approaches to cardiovascular care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.